诊断前后常用镇痛药使用与卵巢癌预后:NHS/NHSII队列研究
该研究基于NHS和NHSII两个前瞻性队列,纳入1143例I-III期上皮性卵巢癌患者,分析诊断前后规律使用阿司匹林、非阿司匹林NSAIDs或对乙酰氨基酚与卵巢癌特异性生存的关系。
要点
- 诊断后近期使用阿司匹林或非阿司匹林NSAIDs与卵巢癌特异性生存改善相关。
- 诊断前任何镇痛药使用及诊断后对乙酰氨基酚使用与生存无正相关。
- 从非使用者转为近期使用阿司匹林或NSAIDs者死亡风险更低。
核心结论
- 诊断后过去2年内近期使用阿司匹林或非阿司匹林NSAIDs似乎改善卵巢癌特异性生存。
研究设计与样本
- 共1143例确诊为侵袭性I-III期上皮性卵巢癌且具备镇痛药使用数据的参与者纳入分析。
- 1031例(90%)纳入诊断前暴露分析,964例(84%)纳入诊断后暴露分析。
- 采用Cox比例风险回归计算风险比(HR)和95%CI,调整年龄、诊断年份、分期和组织学。
主要发现
- 诊断前任何类型镇痛药使用及诊断后对乙酰氨基酚使用与卵巢癌特异性生存无正相关。
临床怎么用
- 对于卵巢癌患者,诊断后近期使用阿司匹林或非阿司匹林NSAIDs可能与更好的特异性生存相关。
- 现有证据不支持为改善卵巢癌预后而常规推荐对乙酰氨基酚或诊断前启动镇痛药。
- 若结果被进一步研究证实,可探索抗炎药物与标准卵巢癌治疗联合的协同效应。
局限性
- 研究为观察性队列,不能确立因果关系。
- 镇痛药使用为自我报告,可能存在暴露错分。
- 结果需在进一步研究中确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ovarian cancer is the fifth most common cause of cancer death among women in the USA. In this study, our objective was to determine whether modifiable exposures to common analgesics outside of standard treatment influence prognosis in patients with ovarian cancer. METHODS: The Nurses' Health Study (NHS) and Nurses' Health Study II (NHSII) are ongoing prospective studies of 121 700 and 116 429 US nurses who have completed biennial questionnaires since 1976 and 1989, respectively. We retrieved information from medical records, death certificates, or linkage to a state or Surveillance, Epidemiology, and End Results (SEER) cancer registry on ovarian cancer cases. Eligible participants had confirmed invasive, stage I-III epithelial ovarian cancer, and had data available on analgesic use. The primary objective was to determine whether self-reported regular use (≥2 days per week) of aspirin, non-aspirin non-steroidal anti-inflammatory drugs (NSAIDs), or paracetamol before and after ovarian cancer diagnosis, was associated with ovarian cancer-specific survival. We used Cox proportional hazards regression to calculate hazard ratios (HRs) and 95% CIs for these associations, adjusting for age and year of diagnosis, disease stage, and histology. FINDINGS: Between June 1, 1976, and May 31, 2012, for the NHS and between June 1, 1989, and May 31, 2013, for NHSII, 1789 participants of the NHS and NHSII studies were diagnosed with epithelial ovarian cancer and 1143 (64%) were eligible to be included in this study; 1031 (90%) of 1143 cases were included in the pre-diagnosis exposure analysis and 964 cases (84%) in the post-diagnosis exposure analysis. Compared with never-users, participants who reported recent (current use in the past 2 years) post-diagnosis use of aspirin (HR 0·68 [95% CI 0·52-0·89]) and non-aspirin NSAIDs (HR 0·67 [95% CI 0·51-0·87]) had an improved ovarian cancer-specific survival. Any type of analgesic use pre-diagnosis, and post-diagnosis use of paracetamol, were not positively associated with ovarian cancer-specific survival. In analyses of change in analgesic use from pre-diagnosis to post-diagnosis, those participants who became recent users of aspirin (HR 0·44 [95% CI 0·26-0·74]) or became recent users of non-aspirin NSAIDs (HR 0·46 [95% CI 0·29-0·73]) post-diagnosis had a lower risk of ovarian cancer-specific death than never-users. INTERPRETATION: Recent use of aspirin or non-aspirin NSAIDs, defined as current use in the past 2 years, after diagnosis appears to improve ovarian cancer-specific survival. If these results are confirmed in further studies, further research should explore potential synergistic effects of anti-inflammatory medications used in combination with standard ovarian cancer therapies to improve the prognosis for patients diagnosed with ovarian cancer. FUNDING: National Institutes of Health, National Cancer Institute, The Marsha Rivkin Center for Ovarian Cancer Research.
引用
- Merritt MA, Rice MS, Barnard ME, et al. Pre-diagnosis and post-diagnosis use of common analgesics and ovarian cancer prognosis (NHS/NHSII): a cohort study. Lancet Oncol. 2018. PMID: 30029888. doi:10.1016/S1470-2045(18)30373-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。